Skin cancer in organ transplant recipients: More than the immune system

Lee Wheless, Sarah Jacks, Kathryn Anne Mooneyham Potter, Brian C. Leach, Joel Cook

Research output: Contribution to journalReview article

Abstract

Organ transplant recipients (OTRs) are at increased risk of developing nonmelanoma skin cancers. This has long been thought to be caused by immunosuppression and viral infection. However, skin cancer risk among individuals with AIDS or iatrogenic immunodeficiency does not approach the levels seen in OTRs, suggesting other factors play a critical role in oncogenesis. In clinical trials of OTRs, switching from calcineurin inhibitors to mammalian target of rapamycin inhibitors consistently led to a significant reduction in the risk of developing new skin cancers. New evidence suggests calcineurin inhibitors interfere with p53 signaling and nucleotide excision repair. These two pathways are associated with nonmelanoma skin cancer, and squamous cell carcinoma in particular. This finding may help explain the predominance of squamous cell carcinoma over basal cell carcinoma in this population. Mammalian target of rapamycin inhibitors do not appear to impact these pathways. Immunosuppression, viral infection, and impaired DNA repair and p53 signaling all interact in OTRs to create a phenotype of extreme risk for nonmelanoma skin cancer.

Original languageEnglish (US)
Pages (from-to)359-365
Number of pages7
JournalJournal of the American Academy of Dermatology
Volume71
Issue number2
DOIs
StatePublished - Aug 2014
Externally publishedYes

Fingerprint

Skin Neoplasms
Immune System
Transplants
Virus Diseases
Sirolimus
DNA Repair
Immunosuppression
Squamous Cell Carcinoma
Basal Cell Carcinoma
Risk Reduction Behavior
Carcinogenesis
Acquired Immunodeficiency Syndrome
Transplant Recipients
Clinical Trials
Phenotype
Population
Calcineurin Inhibitors

Keywords

  • calcineurin inhibitors
  • immunosuppression
  • mammalian target of rapamycin inhibitors
  • oncogenic viruses
  • organ transplant recipients
  • skin cancer

ASJC Scopus subject areas

  • Dermatology

Cite this

Skin cancer in organ transplant recipients : More than the immune system. / Wheless, Lee; Jacks, Sarah; Mooneyham Potter, Kathryn Anne; Leach, Brian C.; Cook, Joel.

In: Journal of the American Academy of Dermatology, Vol. 71, No. 2, 08.2014, p. 359-365.

Research output: Contribution to journalReview article

Wheless, Lee ; Jacks, Sarah ; Mooneyham Potter, Kathryn Anne ; Leach, Brian C. ; Cook, Joel. / Skin cancer in organ transplant recipients : More than the immune system. In: Journal of the American Academy of Dermatology. 2014 ; Vol. 71, No. 2. pp. 359-365.
@article{9d1fc7428e2841dc89ff38079a0a2c1b,
title = "Skin cancer in organ transplant recipients: More than the immune system",
abstract = "Organ transplant recipients (OTRs) are at increased risk of developing nonmelanoma skin cancers. This has long been thought to be caused by immunosuppression and viral infection. However, skin cancer risk among individuals with AIDS or iatrogenic immunodeficiency does not approach the levels seen in OTRs, suggesting other factors play a critical role in oncogenesis. In clinical trials of OTRs, switching from calcineurin inhibitors to mammalian target of rapamycin inhibitors consistently led to a significant reduction in the risk of developing new skin cancers. New evidence suggests calcineurin inhibitors interfere with p53 signaling and nucleotide excision repair. These two pathways are associated with nonmelanoma skin cancer, and squamous cell carcinoma in particular. This finding may help explain the predominance of squamous cell carcinoma over basal cell carcinoma in this population. Mammalian target of rapamycin inhibitors do not appear to impact these pathways. Immunosuppression, viral infection, and impaired DNA repair and p53 signaling all interact in OTRs to create a phenotype of extreme risk for nonmelanoma skin cancer.",
keywords = "calcineurin inhibitors, immunosuppression, mammalian target of rapamycin inhibitors, oncogenic viruses, organ transplant recipients, skin cancer",
author = "Lee Wheless and Sarah Jacks and {Mooneyham Potter}, {Kathryn Anne} and Leach, {Brian C.} and Joel Cook",
year = "2014",
month = "8",
doi = "10.1016/j.jaad.2014.02.039",
language = "English (US)",
volume = "71",
pages = "359--365",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Skin cancer in organ transplant recipients

T2 - More than the immune system

AU - Wheless, Lee

AU - Jacks, Sarah

AU - Mooneyham Potter, Kathryn Anne

AU - Leach, Brian C.

AU - Cook, Joel

PY - 2014/8

Y1 - 2014/8

N2 - Organ transplant recipients (OTRs) are at increased risk of developing nonmelanoma skin cancers. This has long been thought to be caused by immunosuppression and viral infection. However, skin cancer risk among individuals with AIDS or iatrogenic immunodeficiency does not approach the levels seen in OTRs, suggesting other factors play a critical role in oncogenesis. In clinical trials of OTRs, switching from calcineurin inhibitors to mammalian target of rapamycin inhibitors consistently led to a significant reduction in the risk of developing new skin cancers. New evidence suggests calcineurin inhibitors interfere with p53 signaling and nucleotide excision repair. These two pathways are associated with nonmelanoma skin cancer, and squamous cell carcinoma in particular. This finding may help explain the predominance of squamous cell carcinoma over basal cell carcinoma in this population. Mammalian target of rapamycin inhibitors do not appear to impact these pathways. Immunosuppression, viral infection, and impaired DNA repair and p53 signaling all interact in OTRs to create a phenotype of extreme risk for nonmelanoma skin cancer.

AB - Organ transplant recipients (OTRs) are at increased risk of developing nonmelanoma skin cancers. This has long been thought to be caused by immunosuppression and viral infection. However, skin cancer risk among individuals with AIDS or iatrogenic immunodeficiency does not approach the levels seen in OTRs, suggesting other factors play a critical role in oncogenesis. In clinical trials of OTRs, switching from calcineurin inhibitors to mammalian target of rapamycin inhibitors consistently led to a significant reduction in the risk of developing new skin cancers. New evidence suggests calcineurin inhibitors interfere with p53 signaling and nucleotide excision repair. These two pathways are associated with nonmelanoma skin cancer, and squamous cell carcinoma in particular. This finding may help explain the predominance of squamous cell carcinoma over basal cell carcinoma in this population. Mammalian target of rapamycin inhibitors do not appear to impact these pathways. Immunosuppression, viral infection, and impaired DNA repair and p53 signaling all interact in OTRs to create a phenotype of extreme risk for nonmelanoma skin cancer.

KW - calcineurin inhibitors

KW - immunosuppression

KW - mammalian target of rapamycin inhibitors

KW - oncogenic viruses

KW - organ transplant recipients

KW - skin cancer

UR - http://www.scopus.com/inward/record.url?scp=84904743986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904743986&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2014.02.039

DO - 10.1016/j.jaad.2014.02.039

M3 - Review article

C2 - 24725477

AN - SCOPUS:84904743986

VL - 71

SP - 359

EP - 365

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 2

ER -